Hot spots for molecular genetic alterations in lung cancer

In Vivo

Volumn 12, Issue 6, 1998, Pages 643-658

  Pitterle, Diana M ^a   Jolicoeur, Ethel M C ^a   Bepler, Gerold ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allele loss; CDKN2; Cell cycle; Chromosome 11; Chromosome 3; Chromosome 9; LOH11A; LOH11B; Lung cancer; p53; Rb

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; DNA; HYDROLASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; RETINOBLASTOMA PROTEIN; TALIN; TROPOMYOSIN; UBIQUITIN PROTEIN LIGASE;

CANCER GENETICS; CHROMOSOME 11P; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 3P; CHROMOSOME 9P; GENE LOCATION; HETEROZYGOSITY LOSS; HUMAN; LUNG CANCER; MUTATION RATE; ONCOGENE H RAS; REVIEW; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0032436163     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics. Calif Cancer J Clin 47: 5-27, 1997.
2. Ooi WL, Elston RC, Chen VW, Bailey-Wilson JE and Rothschild H: Increased familial risk for lung cancer. J Natl Cancer Inst 76: 217-222, 1986.
3. Sellers TA, Bailey-Wilson JE, Elston RC, Wilson AF, Elston GZ, Ooi WL and Rothschild H: Evidence for Mendelian inheritance in the pathogenesis of lung cancer. J Natl Cancer Inst 82: 1272-1279, 1990.
4. Gauderman W, Morrison J, Carpenter C and Thomas D: Analysis of gene-smoking interaction in lung cancer. Genet Epidemiol 14: 199-214, 1997.
5. Dirks PB and Rutka JT: Current concepts in neuro-oncology: the cell cycle-a review. Neurosurg 40: 1000-1013; discussion 1013-1015, 1997.
6. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-330, 1995.
7. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age [see comments]. Cell 79: 573-582, 1994.
8. Larsen CJ: p16INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene 12: 2041-2044, 1996.
9. Palmero I and Peters G: Perturbation of cell cycle regulators in human cancer. Cancer Surv 27: 351-367, 1996.
10. Minna JD: The molecular biology of lung cancer pathogenesis. Chest 103: 449S-456S, 1993.
11. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL and et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 9: 2441-2448, 1994.
12. Otterson GA, Kratzke RA, Coxon A, Kim YW and Kaye FJ: Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene 9: 3375-3378, 1994.
13. Otterson GA, Khleif SN, Chen W, Coxon AB and Kaye FJ: CDKN2 gene silencing in lung cancer by DNA hypermethylahon and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine. Oncogene 11: 1211-1216, 1995.
14. Kratzke RA, Shimizu E, Geradts J, Gerster JL, Segal S, Otterson GA and Kaye FJ: RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. Cell Growth Diff 4: 629-635, 1993.
15. Huang HJ, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, Lee EY and Lee WH: Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242: 1563-1536, 1988.
16. Jin X, Nguyen D, Zhang WW, Kyritsis AP and Roth JA: Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res 55: 3250-3253, 1995.
17. Shapiro GI and Rollins BJ: p16INK4A as a human tumor suppressor. Biochim Biophys Acta 1242: 165-169, 1996.
18. Lee JM and Bernstein A: Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 14: 149-161, 1995.
19. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-449, 1989.
20. Mitsudomi T, Steinberg S, Nau M, Carbone D, D'Amico D, Bodner S, Oie H, Linnoila R, Mulshine J, Minna J and Gazdar A: p53 gene mutations in non-small-cell lung cancer, cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180, 1992.
21. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T and Ueda R: p53 mutations in non-small cell lung cancer in Japan: association between mutations and. smoking. Cancer Res 52: 734-736, 1992.
22. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R and Minna JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52: 2340-2343, 1992.
23. Naylor SL, Johnson BE, Minna JD and Sakaguchi AY: Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329: 451-454, 1987.
24. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF and Minna JD: Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 215: 181-182, 1982.
25. Brauch H, Tory K, Kotler F, Gazdar AF, Pettengill OS, Johnson B, Graziano S, Winton T, Buys CH, Sorenson GD and et al.: Molecular mapping of deletion sites in the short arm of chromosome 3 in human lung cancer. Genes Chrom Cancer 1: 240-246, 1990.
26. Whang-Peng J, Knutsen T, Gazdar A, Steinberg SM, Oie H, Linnoila I, Mulshine J, Nau M and Minna JD: Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chrom Cancer 3: 168-188, 1991.
27. Petersen I, Bujard M, Petersen S, Wolf G, Goeze A, Schwendel A, Langreck H, Gellert K, Reichel M, Just K, du Manoir S, Cremer T, Dietel M and Ried T: Patterns of chromosomal imbalances in adenpcarcinoma and squamous cell carcinoma of the lung. Cancer Res 57: 2331-2335, 1997.
28. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, Nakamura Y and Takahashi T: Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7: 445-449, 1992.
29. Buchhagen DL: Frequent involvement of chromosome 3p alterations in lung carcinogenesis: allelotypes of 215 established cell lines at six chromosome 3p loci. J Cell Biochem (Suppl) 24: 198-209, 1996.
30. Hung J, Kishimoto Y, Sugio K, Virmani A, McIntire DD, Minna JD and Gazdar AF: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma [published erratum appears in JAMA 1995 Jun 28;273(24):1908]. JAMA 273: 558-563, 1995.
31. Kok K, Naylor SL and Buys CH: Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv Cancer Res 71: 27-92, 1997.
32. Zbar B: Von Hippel-Lindau disease and sporadic renal cell, carcinoma. Cancer Surv 25: 219-232, 1995.
33. Decker HJ, Weidt EJ and Brieger J: The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet 93: 74-83, 1997.
34. Sekido Y, Bader S, Latif F, Gnarra JR, Gazdar AF, Linehan WM, Zbar B, Lerman MI and Minna JD: Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene 9: 1599-1604, 1994.
35. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L and et al: Identification of the von Hippel-Lindau disease tumor suppressor gene [see comments]. Science 260: 1317-1320, 1993.
36. Iliopoulos O, Kibel A, Gray S and Kaelin WG, Jr.: Tumour suppression by the human von Hippel-Lindau gene product. Nature Med 1: 822-826, 1995.
37. Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM and Klausner RD: Nuclear/cytoplasmic localization of the von HippelLindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 93: 1770-1775, 1996.
38. Corless CL, Kibel AS, Iliopoulos O and Kaelin WG, Jr.: Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Human Pathol 28: 459-464, 1997.
39. Duan DR, Pause A, Burgess WH, Aso T, Chen DY, Garrett KP, Conaway RC, Conaway JW, Linehan WM and Klausner RD: Inhibition of transcription elongation by the VHL tumor suppressor protein [see comments]. Science 269: 1402-6, 1995.
40. Duan DR, Humphrey JS, Chen DY, Weng Y, Sukegawa J, Lee S, Gnarra JR, - Linehan WM and Klausner RD: Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci USA 92: 6459-6463, 1995.
41. Kibel A, Iliopoulos O, DeCaprio JA and Kaelin WG, Jr.: Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C [see comments]. Science 269: 1444-1446, 1995.
42. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, Kumamoto Y, Sugimura T and Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233-4237, 1994.
43. Gnarra JR, Zhou S, Merrill MJ, Wagner JR, Krumm A, Papavassiliou E, Oldfield EH, Klausner RD and Linehan WM: Posttranscriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 93: 10589-10594, 1996.
44. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L and Zbar B: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 55: 4804-4807, 1995.
45. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A et al: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368: 258-261, 1994.
46. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD and et al: Mutation of a mutL homolog in hereditary colon cancer [see comments]. Science 263: 1625-1629, 1994.
47. Modrich P and Lahue R: Mismatch repair in replication fidelity, genetic recombination, and cancer biology. Annual Review of Biochemistry 65: 101-133, 1996.
48. Jiricny J: Mismatch repair and cancer. Cancer Surv 28: 47-68, 1996.
49. Mauillon JL, Michel P, Limacher JM, Latouche JB, Dechelotte P, Charbonnier F, Martin C, Moreau V, Metayer J, Paillot B and Frebourg T: Identification of novel germline hMLH1 mutations including a 22 kb Alu-mediated deletion in patients with familial colorectal cancer. Cancer Res 56: 5728-33, 1996.
50. Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham JM, French AJ, Halling KC, Schwab M, Goretzki P and Thibodeau SN: Microsatellite instability and mutation analysis of hMSH2 and hMLH1 in patients with sporadic, familial and hereditary colorectal cancer. Human Mol Genet 5: 1245-1252, 1996.
51. Wieland I, Ammermuller T, Bohm M, Totzeck B and Rajewsky MF: Microsatellite instability and loss of heterozygosity at the hMLH1 locus on chromosome 3p21 occur in a subset of nonsmall cell lung carcinomas. Oncology Res 8: 1-5, 1996.
52. Thiberville L, Bourguignon J, Metayer J, Bost F, Diarra-Mehrpour M, Bignon J, Lam S, Martin JP and Nouvet G: Frequency and prognostic evaluation of 3p21-22 allelic losses in non-smalt-cell lung cancer. Int J Cancer 64: 371-377, 1995.
53. Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker CE, Jr., Hahner L, Anderson M, Wiest JS, Drabkin HA and Gemmill RM: Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res 57: 1344-1352, 1997.
54. van den Berg A and Buys CH: Involvement of multiple loci on chromosome 3 in renal cell cancer development. Genes Chrom Cancer 19: 59-76, 1997.
55. Killary AM, Wolf ME, Giambernardi TA and Naylor SL: Definition of a tumor suppressor locus within human chromosome 3p21-p22. Proc Natl Acad Sci USA 89: 10877-10881, 1992.
56. Todd MC, Xiang RH, Garcia DK, Kerbacher KE, Moore SL, Hensel CH, Liu P, Siciliano MJ, Kok K, van den Berg A, Veldhuis P, Buys CH, Killary AM and Naylor SL: An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo. Oncogene 13: 2387-2396, 1996.
57. Kok K, Hofstra R, Pilz A, van den Berg A, Terpstra P, Buys CH and Carritt B: A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci USA 90: 6071-6075, 1993.
58. Kok K, van den Berg A, Buchhagen DL, Carritt B and Buys CH: A PCR-aided transcript titration assay revealing very low expression of a gene at band 3p21 in 33 cells lines derived from all types of lung cancer. Eur J Human Genet 1: 156-163, 1993.
59. Kraus C, Liehr T, Hulsken J, Behrens J, Birchmeier W, Grzeschik KH and Ballhausen WG: Localization of the human beta-catenin gene (CTNNBI) to 3p21: a region implicated in tumor development. Genomics 23: 272-274, 1994.
60. Bailey A, Norris AL, Leek JP, Clissold PM, Can IM, Ogilvie DJ, Morrison JF, Meredith DM and Markham AF: Yeast artificial chromosome cloning of the beta-catenin locus on human chromosome 3p21-22. Chromosome Res 3: 201-203, 1995.
61. Gumbiner BM: Carcinogenesis: a balance between beta-catenin and APC. Current Biol 7: R443-6, 1997.
62. Peralta Soler A, Knudsen KA, Jaurand MC, Johnson KR, Wheelock MJ, Klein- Szanto AJ and Salazar H: The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas [see comments]. Human Pathol 26: 1363-9, 1995.
63. Sutherland GR: Chromosomal fragile sites. Genet Anal Tech Appl 8: 161-166, 1991.
64. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T et al: The FHIT gene, spanning the chromosome 3pj4.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597, 1996.
65. Huebner K, Hadaczek P, Siprashvili Z, Druck T and Croce CM: The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta 1332: M65-70, 1997.
66. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M and Huebner K: Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 35: 11529-11535, 1996.
67. Grummt F: Diadenosine 5′,5‴-P1,P4-tetraphosphate triggers initiation of in vitro DNA replication in baby hamster kidney cells. Proc Natl Acad Sci USA 75: 371-375, 1978.
68. Grummt F, Weinmann-Dorsch C, Schneider-Schaulies J and Lux A: Zinc as a second messenger of mitogenic induction. Effects on diadenosine tetraphosphate (Ap4A) and DNA synthesis. Expl Cell Res 163: 191-200, 1986.
69. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996.
70. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF and Minna JD: FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57: 2256-2267, 1997.
71. Sozzi G, Sard L; De Gregorio L, Marchetti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M, Chella A, Angeletti CA, Pastorino U, Huebner K, Bevilaqua G, Pilotti S, Croce CM and Pierotti MA: Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57: 2121-2123, 1997.
72. Mao L, Fan YH, Lotan R and Hong WK: Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res 56: 5128- 5131, 1996.
73. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Croce CM: The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173-3179, 1996.
74. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K and Croce CM: FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93: 9770-9775, 1996.
75. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC: FHIT mutations in human primary gastric cancer. Cancer Res 57: 1435-1437, 1997.
76. Hayashi S, Tanimoto K, Hajiro-Nakanishi K, Tsuchiya E, Kurosumi M, Higashi Y, Imai K, Suga K and Nakachi K: Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 57: 1981-1985, 1997.
77. Hendricks DT, Taylor R, Reed M and Birrer MJ: FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res 57: 2112-2115, 1997.
78. van den Berg A, Draaijers TG, Kok K, Timmer T, Van der Veen AY, Veldhuis PM, de Leij L, Gerhartz CD, Naylor SL, Smith DI and Buys CH: Normal FHIT transcripts in renal cell cancer- and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chrom Cancer 19: 220-227, 1997.
79. Panagopoulos I, Thelin S, Mertens F, Mitelman F and Aman P: Variable FHIT transcripts in non-neoplastic tissues. Genes Chrom Cancer 19: 215-219, 1997.
80. Zimonjic DB, Druck T, Ohta M, Kastury K, Croce CM, Popescu NC and Huebner K: Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res 57: 1166-1170, 1997.
81. Tory K, Latif F, Modi W, Schmidt L, Wei MH, Li H, Cobler P, Orcutt ML, Delisio J, Geil L et al: A genetic linkage map of 96 loci on the short arm of human chromosome 3. Genomics 13: 275-286, 1992.
82. Tsukamoto T, Takahashi T, Ueda R, Hibi K, Saito H and Takahashi T: Molecular analysis of the protein tyrosine phosphatase gamma gene in human lung cancer cell lines. Cancer Res 52: 3506-3509, 1992.
83. LaForgia S, Morse B, Levy J, Barnea G, Cannizzaro LA, Li F, Nowell PC, Boghosian-Sell L, Glick J, Weston A et al: Receptor protein-tyrosine phosphatase gamma is a candidate tumor suppressor gene at human chromosome region 3p21. Proc Natl Acad Sci USA 88: 5036-5040, 1991.
84. Lukeis R, Ball D, Irving L, Garson OM and Hasthorpe S: Chromosome abnormalities in non-small cell lung cancer pleural effusions: cytogenetic indicators of disease subgroups. Genes Chrom Cancer 8: 262-269, 1993.
85. Testa JR and Graziano SL: Molecular implications of recurrent cytogenetic alterations in human small cell lung cancer. Cancer Detect Prev 17: 267-77, 1993.
86. Testa JR, Siegfried JM, Liu Z, Hunt JD, Feder MM, Litwin S, Zhou JY, Taguchi T and Keller SM: Cytogenetic analysis of 63 non-small cell lung carcinomas: recurrent chromosome alterations amid frequent and widespread genomic upheaval. Genes Chrom Cancer 11: 178-194, 1994.
87. Center R, Lukeis R, Dietzsch E, Gillespic M and Garson OM: Molecular deletion of 9p sequences in non-small cell lung cancer and malignant mesothelioma. Genes Chrom Cancer 7: 47-53, 1993.
88. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD and Diaz MO: Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 55: 2410-2415, 1993.
89. Mead LJ, Gillespie MT, Irving LB and Campbell LJ: Homozygous and hemizygous deletions of 9p centromeric to the interferon genes in lung cancer. Cancer Res 54: 2307-2309, 1994.
90. Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Fong KM, Sekido Y, Minna JD, Hong WK and Mao L: Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res 57: 400-403, 1997.
91. Pittenger MF, Kazzaz JA and Helfman DM: Functional properties of non-muscle tropomyosin isoforms. Current Op Cell Biol 6: 96-104, 1994.
92. Button E, Shapland C and Lawson D: Actin, its associated proteins and metastasis. Cell Motil Cytoskel 30: 247-251, 1995.
93. Prasad GL, Fuldner RA and Cooper HL: Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci USA 90: 7039-7043, 1993.
94. Tsukita S and Yonemura S: ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Current Op Cell Biol 9: 70-5, 1997.
95. Takeuchi K, Sato N, Kasahara H, Funayama N, Nagafuchi A, Yonemura S, Tsukita S and Tsukita S: Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J Cell Biol 125: 1371-1384, 1994.
96. Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K et al: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor [published erratum appears in Cell 1993 Nov 19;75(4):826]. Cell 72: 791-800, 1993.
97. Bepler G and Koehler A: Multiple chromosomal aberrations and 11p allelotyping in lung cancer cell lines. Cancer Genet Cytogenet 84: 39-45, 1995.
98. Bepler G and Garcia-Blanco MA: Three tumor-suppressor regions on chromosome lip identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc Natl Acad Sci USA 91: 5513-5517, 1994.
99. Schreiber G, Fong KM, Peterson B, Johnson BE, O'Briant KC and Bepler G: Smoking, gender, and survival association with allele loss for the LOH11B lung cancer region on chromosome 11. Cancer Epidemiol Biomarker Prev 6: 315-319, 1997.
100. O'Briant KC and Bepler G: Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH1A and LOH11B. Genes Chrom Cancer 18: 111-114, 1997.
101. Bepler G, Fong KM, Johnson BE, O'Briant KC, Daly LA, Zimmerman PV, Garcia-Blanco MA and Peterson B: Association of chromosome 11 locus D11S12 with histology, stage and metastases in lung cancer. Cancer Detect Prev 22: 1-6, 1998.
102. Shiraishi M, Morinaga S, Noguchi M, Shimosato Y and Sekiya T: Loss of genes on the short arm of chromosome 11 in human lung carcinomas. Jpn J Cancer Res 78: 1302-1308, 1987.
103. Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J, Light B, Haugen A, Mann DL, Trump BF and Harris CC: Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocareinoma of the human lung. Proc Natl Acad Sci USA 86: 5099-5103, 1989.
104. Skinner MA, Vollmer R, Huper G, Abbott P and Iglehart JD: Loss of heterozygosity for genes on 11p and the clinical course of patients with lung carcinoma. Cancer Res 50: 2303-2306, 1990.
105. Ludwig CU, Raefle G, Dalquen P, Stulz P, Stahel R and Obrecht JP: Allelic loss on the short arm of chromosome 11 in non-small-cell lung cancer. Intl J Cancer 49: 661-665, 1991.
106. Fong KM, Zimmerman PY and Smith PJ: Correlation of loss of heterozygosity at 11p with tumour progression and survival in non-small cell lung cancer. Genes Chrom Cancer 10: 183-189, 1994.
107. Tran YK and Newsham I, F.: High-density marker analysis of 1 1p1S.5 in non- small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res 56: 2916-2921, 1996.
108. Ali IU, Lidereau R, Theillet C and Callahan R: Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science 238: 185-188, 1987.
109. Theillet C, Lidereau R, Escot C, Hutzell P, Brunet M, Gest J, Schlom J and Callahan R: Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res 46: 4776-4781, 1986.
110. Scrable H, Cavenee W, Ghavimi F, Lovell M, Morgan K and Sapienza C: A model for embryonal rhabdomyosarcoma tumorigenesis that involves genome imprinting. Proc Natl Acad Sci USA 86: 7480-7484, 1989.
111. Radice P, Pierotti MA, Lacerenza S, Mondini P, Radice MT, Pilotti S and Della Porta G: Loss of heterozygosity in human germinal tumors. Cytogenet Cell Genet 52: 72-76, 1989.
112. Fearon ER, Feinberg AP, Hamilton SH and Vogelstein B: Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318: 377-380, 1985.
113. Shibagaki I, Shimada Y, Wagata T, Ikenaga M, Imamura M and Ishizaki K: Allelotype analysis of esophageal squamous cell carcinoma. Cancer Res 54: 2996-3000, 1994.
114. Lu K, JN W, Kodali S, Welch W, Berkowitz R and Mok S: A novel 4-cM minimally deleted region on chromosome 1 IplS. I associated with high grade nonmucinous epithelial ovarian carcinomas. Cancer Res 57: 387-390, 1997.
115. Winqvist R, Mannermaa A, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi K, Newsham I and Cavenee W: Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors. Cancer Res 53: 4486-4488, 1993.
116. Sager R: Tumor suppressor genes: the puzzle and the promise. Science 246: 1406-1412, 1989.
117. O'Briant K, Jolicoeur E, Garst J, Campa M, Schreiber G and Bepler G: Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11. Anticancer Res 17: 3243-3252, 1997.
118. Ohno S: Dispensable genes. Trends Genet 1: 160-164, 1985.
119. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.